undamentalytics Newsletter
Sign in

Legend Biotech Corp cash flow statement

In fiscal 2025, Legend Biotech Corp's operations generated −$100m of cash; it spent $28.6m on capital projects, leaving free cash flow of −$129m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations308−83−223−198−201−393−144−100
Capital spending2127264221201429
Free cash flow287−110−249−241−222−413−158−129

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: KNSA vs LEGNBBIO vs LEGNBCRX vs LEGNACAD vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Legend Biotech Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Legend Biotech Corp.